Share Price and Basic Stock Data
Last Updated: February 14, 2026, 10:06 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chemo Pharma Laboratories Ltd operates within the pharmaceutical sector, with a current market capitalization of ₹16.4 Cr. The company’s stock price is reported at ₹109, reflecting the challenges it faces in generating revenue. Notably, Chemo Pharma has reported zero sales across multiple quarters, dating from September 2022 through December 2024. This consistent lack of revenue indicates significant operational hurdles and raises concerns about the company’s market viability. Despite this, the company reported a marginal sales figure of ₹0.53 lakh for September 2025, which may suggest an initial step towards recovery. The absence of sales revenue over such an extended period is atypical for the pharmaceutical industry, where companies typically generate steady revenue streams from product sales. This trend emphasizes the urgent need for Chemo Pharma to reassess its operational strategies and product offerings to enhance its revenue generation capabilities.
Profitability and Efficiency Metrics
Chemo Pharma Laboratories Ltd’s profitability metrics reveal a challenging financial landscape. The company’s reported operating profit margin (OPM) stood at 18.87% as of September 2025, which is commendable compared to many firms but is overshadowed by its negative net profit of ₹12 lakh for the same period. The company has experienced fluctuating net profits over the past years, with a notable decline to a loss of ₹11.81 lakh in June 2025. The trailing twelve months (TTM) figures indicate a total net profit of -₹12 lakh, a stark contrast to the industry norms where profitability is often a key indicator of operational success. The return on equity (ROE) is recorded at a low 3.47%, while the return on capital employed (ROCE) is slightly better at 5.17%, indicating that while some operational efficiency exists, it is not translating into overall profitability. The financial metrics highlight the need for strategic improvements to transform operational efficiencies into sustainable profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Chemo Pharma Laboratories Ltd presents a mixed picture of financial health. The company has reported no borrowings, which indicates a debt-free status, potentially providing a buffer against financial distress. However, the reserves are also reported at ₹0 Cr, reflecting a lack of retained earnings to support future growth or operational contingencies. The price-to-book value (P/BV) ratio is recorded at 0.72x, suggesting that the market is valuing the company below its book value, which could indicate undervaluation or market skepticism about its future prospects. The interest coverage ratio (ICR) is not applicable, given the absence of interest expenses. The current ratio and quick ratio remain unreported but are critical in assessing the company’s liquidity position. Overall, while the absence of debt may be a strength, the lack of reserves raises concerns regarding the company’s ability to withstand financial challenges.
Shareholding Pattern and Investor Confidence
Chemo Pharma’s shareholding pattern reveals a diverse ownership structure with promoters holding 27.89% of the equity as of September 2025. The public holds a significant majority at 71.75%, while domestic institutional investors (DIIs) hold a minimal 0.17%. This distribution indicates a potential lack of institutional confidence, which is often crucial for stability in stock performance. The number of shareholders as of September 2025 stands at 6,409, reflecting a steady interest among retail investors despite the company’s financial challenges. The consistent promoter holding suggests a commitment to the company’s long-term vision, but the low presence of institutional investment may hinder access to capital for growth initiatives. The shareholding dynamics imply that while there is a base of retail support, the company needs to bolster investor confidence through improved financial performance and strategic initiatives to attract institutional investors.
Outlook, Risks, and Final Insight
Looking ahead, Chemo Pharma Laboratories Ltd faces significant risks and opportunities. The consistent lack of revenue poses a critical challenge that must be addressed for any positive outlook. However, the recently recorded sales in September 2025 could signal the beginning of a turnaround, provided the company can sustain this momentum. Key strengths include its debt-free status and a commendable OPM, which could enable strategic investments in product development or marketing. Conversely, the absence of reserves and the negative net profit present substantial risks that could affect operational viability and investor sentiment. The potential for recovery hinges on the company’s ability to innovate and market its products effectively. If Chemo Pharma can leverage its strengths while addressing its financial shortcomings, it may position itself for a more stable and profitable future in the pharmaceutical industry.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 137/84.3 | 26.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,402 Cr. | 312 | 479/192 | 71.2 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 28.3 Cr. | 38.2 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 84.4 Cr. | 57.6 | 57.6/17.0 | 338 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,956.81 Cr | 1,098.00 | 54.79 | 201.74 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.53 |
| Expenses | 0.05 | 0.02 | 0.02 | 0.05 | 0.02 | 0.02 | 0.10 | 0.05 | 0.02 | 0.02 | 0.02 | 11.83 | 0.43 |
| Operating Profit | -0.05 | -0.02 | -0.02 | -0.05 | -0.02 | -0.02 | -0.10 | -0.05 | -0.02 | -0.02 | -0.02 | -11.83 | 0.10 |
| OPM % | 18.87% | ||||||||||||
| Other Income | 0.59 | 0.19 | -0.10 | 0.43 | 0.46 | 0.70 | 0.25 | 0.30 | 0.63 | -0.15 | -0.16 | 0.02 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.54 | 0.17 | -0.12 | 0.38 | 0.44 | 0.68 | 0.15 | 0.25 | 0.61 | -0.17 | -0.18 | -11.81 | 0.10 |
| Tax % | 0.00% | 0.00% | 25.00% | 0.00% | 0.00% | 0.00% | 293.33% | 0.00% | 0.00% | 0.00% | 88.89% | 0.00% | 0.00% |
| Net Profit | 0.53 | 0.16 | -0.15 | 0.38 | 0.44 | 0.68 | -0.29 | 0.25 | 0.61 | -0.17 | -0.34 | -11.81 | 0.10 |
| EPS in Rs | 3.53 | 1.07 | -1.00 | 2.53 | 2.93 | 4.53 | -1.93 | 1.67 | 4.07 | -1.13 | -2.27 | -78.73 | 0.67 |
Last Updated: December 27, 2025, 2:04 pm
Below is a detailed analysis of the quarterly data for Chemo Pharma Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.53 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Jun 2025) to 0.53 Cr., marking an increase of 0.53 Cr..
- For Expenses, as of Sep 2025, the value is 0.43 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.83 Cr. (Jun 2025) to 0.43 Cr., marking a decrease of 11.40 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.10 Cr.. The value appears strong and on an upward trend. It has increased from -11.83 Cr. (Jun 2025) to 0.10 Cr., marking an increase of 11.93 Cr..
- For OPM %, as of Sep 2025, the value is 18.87%. The value appears strong and on an upward trend. It has increased from 0.00% (Jun 2025) to 18.87%, marking an increase of 18.87%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.02 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 0.02 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.10 Cr.. The value appears strong and on an upward trend. It has increased from -11.81 Cr. (Jun 2025) to 0.10 Cr., marking an increase of 11.91 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 0.10 Cr.. The value appears strong and on an upward trend. It has increased from -11.81 Cr. (Jun 2025) to 0.10 Cr., marking an increase of 11.91 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.67. The value appears strong and on an upward trend. It has increased from -78.73 (Jun 2025) to 0.67, marking an increase of 79.40.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:58 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -12 |
| OPM % | -2,221% | ||||||||||||
| Other Income | 0 | 0 | 0 | 6 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | -0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | -12 |
| Tax % | 19% | 26% | 31% | 12% | 86% | 19% | 16% | 19% | -56% | 38% | 27% | 33% | |
| Net Profit | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | -12 |
| EPS in Rs | 1.60 | 1.87 | 1.47 | 31.20 | 0.67 | 1.40 | 2.80 | 1.67 | 3.73 | 0.33 | 8.00 | 2.27 | -81.46 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2022-2023 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | -100.00% | -100.00% | -100.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
Chemo Pharma Laboratories Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 3 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -4% |
| 3 Years: | -4% |
| TTM: | -1184% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 64% |
| 3 Years: | 54% |
| 1 Year: | 65% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: December 10, 2025, 4:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves | 3 | 4 | 4 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 11 | 12 | -0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Total Liabilities | 5 | 6 | 6 | 11 | 10 | 10 | 11 | 11 | 12 | 12 | 13 | 13 | 2 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 4 | 0 | 0 |
| Other Assets | 4 | 4 | 4 | 11 | 10 | 10 | 11 | 11 | 9 | 9 | 9 | 13 | 2 |
| Total Assets | 5 | 6 | 6 | 11 | 10 | 10 | 11 | 11 | 12 | 12 | 13 | 13 | 2 |
Below is a detailed analysis of the balance sheet data for Chemo Pharma Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 12.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. However, Reserves are negative, which is a major warning sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing). It has decreased from 13.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 11.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 11.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 11.00 Cr..
Reserves and Borrowings are well balanced.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | ||||||||||||
| Working Capital Days | ||||||||||||
| ROCE % | 7% | 8% | 6% | 4% | 8% | 3% | 5% | 3% | 1% | 1% | 13% | 5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 16 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | -9.66 |
| Diluted EPS (Rs.) | -9.66 |
| Cash EPS (Rs.) | -9.66 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 24.49 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 24.49 |
| PBDIT / Share (Rs.) | -8.98 |
| PBIT / Share (Rs.) | -8.98 |
| PBT / Share (Rs.) | -8.98 |
| Net Profit / Share (Rs.) | -9.66 |
| NP After MI And SOA / Share (Rs.) | -9.66 |
| Return on Networth / Equity (%) | -39.44 |
| Return on Capital Employeed (%) | -35.51 |
| Return On Assets (%) | -37.44 |
| Current Ratio (X) | 28.82 |
| Quick Ratio (X) | 28.82 |
| Enterprise Value (Cr.) | 2.24 |
| EV / EBITDA (X) | -1.66 |
| Price / BV (X) | 0.72 |
| EarningsYield | -0.54 |
After reviewing the key financial ratios for Chemo Pharma Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 16, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 24.49. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 24.49. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 0. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 0. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 16, the value is -39.44. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 16, the value is -35.51. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 16, the value is -37.44. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 16, the value is 28.82. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 16, the value is 28.82. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 16, the value is 2.24. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 16, the value is -1.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 16, the value is 0.72. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 16, the value is -0.54. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemo Pharma Laboratories Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -35.51% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -39.44% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 28.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 54.79)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 5, Kumud Apartment CHS Ltd., Thane District Maharashtra 421301 | chemopharmalab@gmail.com http://www.thechemopharmalaboratoriesltd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bhavin Sheth | Executive Director & CEO |
| Mr. Ashok Somani | Executive Director & CFO |
| Mrs. Shanta Somani | Non Executive Director |
| Mr. Mathura Prasad Sharma | Independent Director |
| Mr. Toby Antony | Independent Director |
| Mr. Nandkumar Pareek | Independent Director |
FAQ
What is the intrinsic value of Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd's intrinsic value (as of 15 February 2026) is ₹1.67 which is 98.41% lower the current market price of ₹105.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹15.8 Cr. market cap, FY2025-2026 high/low of ₹153/70.0, reserves of ₹-0 Cr, and liabilities of ₹2 Cr.
What is the Market Cap of Chemo Pharma Laboratories Ltd?
The Market Cap of Chemo Pharma Laboratories Ltd is 15.8 Cr..
What is the current Stock Price of Chemo Pharma Laboratories Ltd as on 15 February 2026?
The current stock price of Chemo Pharma Laboratories Ltd as on 15 February 2026 is ₹105.
What is the High / Low of Chemo Pharma Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chemo Pharma Laboratories Ltd stocks is ₹153/70.0.
What is the Stock P/E of Chemo Pharma Laboratories Ltd?
The Stock P/E of Chemo Pharma Laboratories Ltd is .
What is the Book Value of Chemo Pharma Laboratories Ltd?
The Book Value of Chemo Pharma Laboratories Ltd is 9.60.
What is the Dividend Yield of Chemo Pharma Laboratories Ltd?
The Dividend Yield of Chemo Pharma Laboratories Ltd is 0.00 %.
What is the ROCE of Chemo Pharma Laboratories Ltd?
The ROCE of Chemo Pharma Laboratories Ltd is 5.17 %.
What is the ROE of Chemo Pharma Laboratories Ltd?
The ROE of Chemo Pharma Laboratories Ltd is 3.47 %.
What is the Face Value of Chemo Pharma Laboratories Ltd?
The Face Value of Chemo Pharma Laboratories Ltd is 10.0.